Congress tightens rules on drug discounts for safety-net hospitals
H.R. 4581 — 340B PATIENTS Act of 2025 · Filed by Doris Matsui (D-CA) · 21 cosponsors · Introduced Jul 22, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill clarifies that drug manufacturers participating in the 340B discount program must offer discounted prices to covered entities (hospitals, clinics, health centers) regardless of how or where the drugs are dispensed—including through contract pharmacies—and prohibits manufacturers from placing conditions on these discounts. It also establishes civil penalties (up to $2 million per day) for manufacturers who violate these requirements and creates a process for covered entities to report violations.
Why we flagged it
The bill's core function is to enforce and clarify existing 340B program rules to ensure covered entities can use discounts flexibly, particularly through contract pharmacies, to maximize patient access to discounted drugs. It is a regulatory clarification and enforcement measure, not a new entitlement or subsidy.
What the text implies
- Manufacturers may face significant compliance costs and legal exposure if they have been conditioning 340B discounts on dispensing location or method; the $2M/day penalty creates strong incentive to cease such practices immediately.
- Contract pharmacies—particularly specialty and mail-order pharmacies serving rural or underserved areas—may see increased volume and revenue as covered entities gain clearer legal authority to use them without manufacturer interference.
The full analysis lists 5 implications of this text.
Who stands to gain
covered entities (hospitals, clinics, health centers); contract pharmacies (specialty and mail-order); patients accessing discounted drugs